Drug websites including GoodRx (GDRX) will not be partnering with TrumpRx, CBS News’ Jennifer Jacobs reports, citing sources. One official said the federal government website will send consumers to the pharmaceutical companies’ websites, where they can buy prescription medicines directly, and the companies will decide how to fulfill those orders, the author notes.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx Holdings: Balancing Challenges and Opportunities Amidst PTR Growth Concerns and Pharma Manufacturing Strength
- GoodRx price target lowered to $4 from $4.25 at UBS
- GoodRx price target lowered to $4 from $5 at Mizuho
- Challenging Outlook for GoodRx Holdings Amid Structural and Market Pressures
- Buy Rating for GoodRx Holdings: Strategic Initiatives and Growth Prospects Amid Challenges